Jasper Therapeutics(US:JSPR) Globenewswire·2025-10-10 17:30Core Viewpoint - Jasper Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading statements and failure to disclose material adverse facts regarding its business and clinical trials, particularly related to the briquilimab drug product [3]. Group 1: Company Developments - On July 7, 2025, Jasper announced issues with a drug product lot used in its BEACON Study for Chronic Spontaneous Urticaria, leading to a significant stock price drop of $3.73, or 55.1%, closing at $3.04 per share [2]. - The company is halting the development of briquilimab for asthma and SCID, and is implementing cost-cutting measures, including potential restructuring, to extend its financial runway [2]. Group 2: Lawsuit Details - The class action lawsuit alleges that Jasper's management made materially false and misleading statements and failed to disclose critical information about the company's operational controls and the risks associated with its clinical trials [3]. - Specific allegations include the lack of necessary controls for third-party manufacturers, which increased the risk of confounding study results and negatively impacted the company's regulatory and commercial prospects [3]. Group 3: Legal Actions - Investors who purchased Jasper securities during the class period from November 30, 2023, to July 3, 2025, have until November 18, 2025, to file a lead plaintiff motion in the class action lawsuit [1][4].